# US 2008/0306097 A1 · Cancer Treatment Method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306097 A1
- Document ID: US20080306097A1
- Status: Published application
- Kind: A1
- Application number: 11/721,675
- Filed: 2005-12-16
- Published: 2008-12-11
- Earliest claimed: 2004-12-17
- Assignees: SmithKline Beecham (Cork) Limited
- Inventors: Stephen Rubin
- Web page: https://patentgrep.com/patent/US20080306097A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is a method of treating breast cancer that has metastasized to the brain in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to methods of treating breast cancer brain metastases which overexpress erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A method of treating breast cancer metastases in the brain of a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound of formula (I)
or salts or solvates thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the breast cancer brain metastases overexpress erbB-2.

### Claim 12

A method of treating breast cancer metastases in the brain of a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound of formula (I′)
or solvates thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the breast cancer brain metastases overexpress erbB-2.

### Claim 14

A method of treating breast cancer metastases in the brain of a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound of formula (I″).

### Claim 15 (depends on 14)

The method of claim 14, wherein the breast cancer brain metastases overexpress erbB-2.

### Claim at position 8

16-21. (canceled)

### Claim 22 (depends on 10)

The method of claim 10, wherein the mammal has previously been treated with trastuzumab.

### Claim 23 (depends on 10)

The method of claim 10, further comprising administering a therapeutically effective amount of at least one additional cancer treatment therapy.

### Claim 24 (depends on 23)

The method of claim 23, wherein the at least one additional cancer treatment therapy is radiation therapy.

### Claim 25 (depends on 24)

The method of claim 24, wherein the radiation therapy is stereotactic radiosurgery.

### Claim 26 (depends on 24)

The method of claim 24, wherein the radiation therapy is whole brain radiotherapy.

### Claim 27 (depends on 23)

The method of claim 23, wherein the at least one additional cancer treatment therapy is administration of at least one anti-neoplastic agent.

### Claim 28 (depends on 27)

The method of claim 27, wherein the at least one anti-neoplastic agent is a fluoropyrimidine.

### Claim 29 (depends on 28)

The method of claim 28, wherein the fluoropyrimidine is 5-fluorouracil.

### Claim 30 (depends on 29)

The method of claim 29, wherein the at least one anti-neoplastic agent is an inhibitor of a VEGFR.

### Claim 31 (depends on 10)

The method of claim 10, further comprising administering a therapeutically effective amount of elacridar.

### Claim 32 (depends on 12)

The method of claim 12, wherein the mammal has previously been treated with trastuzumab.

### Claim 33 (depends on 12)

The method of claim 12, further comprising administering a therapeutically effective amount of at least one additional cancer treatment therapy.

### Claim 34 (depends on 33)

The method of claim 33, wherein the at least one additional cancer treatment therapy is radiation therapy.

### Claim 35 (depends on 34)

The method of claim 34, wherein the radiation therapy is stereotactic radiosurgery.

### Claim 36 (depends on 34)

The method of claim 34, wherein the radiation therapy is whole brain radiotherapy.

### Claim 37 (depends on 33)

The method of claim 33, wherein the at least one additional cancer treatment therapy is administration of at least one anti-neoplastic agent.

### Claim 38 (depends on 37)

The method of claim 37, wherein the at least one anti-neoplastic agent is a fluoropyrimidine.

### Claim 39 (depends on 38)

The method of claim 38, wherein the fluoropyrimidine is 5-fluorouracil.

### Claim 40 (depends on 37)

The method of claim 37, wherein the at least one anti-neoplastic agent is an inhibitor of a VEGFR.

### Claim 41 (depends on 12)

The method of claim 12, further comprising administering a therapeutically effective amount of elacridar.

### Claim 42 (depends on 14)

The method of claim 14, wherein the mammal has previously been treated with trastuzumab.

### Claim 43 (depends on 14)

The method of claim 14, further comprising administering a therapeutically effective amount of at least one additional cancer treatment therapy.

### Claim 44 (depends on 43)

The method of claim 43, wherein the at least one additional cancer treatment therapy is radiation therapy.

### Claim 45 (depends on 44)

The method of claim 44, wherein the radiation therapy is stereotactic radiosurgery.

### Claim 46 (depends on 44)

The method of claim 44, wherein the radiation therapy is whole brain radiotherapy.

### Claim 47 (depends on 43)

The method of claim 43, wherein the at least one additional cancer treatment therapy is administration of at least one anti-neoplastic agent.

### Claim 48 (depends on 47)

The method of claim 47, wherein the at least one anti-neoplastic agent is a fluoropyrimidine.

### Claim 49 (depends on 48)

The method of claim 48, wherein the fluoropyrimidine is 5-fluorouracil.

### Claim 50 (depends on 47)

The method of claim 47, wherein the at least one anti-neoplastic agent is an inhibitor of a VEGFR.

### Claim 51 (depends on 14)

The method of claim 14, further comprising administering a therapeutically effective amount of elacridar.
